Dataset from Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto® Respimat® [ELLACTO]

Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations开放标签观察性研究：纳入接受Spiolto® Respimat®治疗约6周的慢性阻塞性肺疾病（COPD）患者，该时长为两次门诊就诊之间的平均间隔时间。